Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $137.08 Consensus PT from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been given a consensus recommendation of “Moderate Buy” by the fifteen research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $137.0769.

Several research analysts have recently weighed in on the company. Citizens Jmp restated a “market outperform” rating and set a $132.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, April 21st. Evercore restated an “outperform” rating and set a $138.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. TD Cowen boosted their target price on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Morgan Stanley boosted their target price on Mirum Pharmaceuticals from $130.00 to $140.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 7,287 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $670,258.26. Following the transaction, the chief financial officer directly owned 49,788 shares in the company, valued at $4,579,500.24. The trade was a 12.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Joanne Quan sold 7,287 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $670,258.26. Following the transaction, the insider owned 18,864 shares in the company, valued at approximately $1,735,110.72. This represents a 27.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 76,806 shares of company stock worth $7,064,616. 14.36% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MIRM. Janus Henderson Group PLC lifted its holdings in Mirum Pharmaceuticals by 21.4% in the fourth quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock valued at $479,050,000 after acquiring an additional 1,067,722 shares during the last quarter. State Street Corp lifted its holdings in Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after acquiring an additional 797,088 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Mirum Pharmaceuticals by 566.8% in the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after acquiring an additional 672,118 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Mirum Pharmaceuticals by 709.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after acquiring an additional 536,674 shares during the last quarter. Finally, Voloridge Investment Management LLC lifted its holdings in Mirum Pharmaceuticals by 2,116.6% in the third quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock valued at $28,560,000 after acquiring an additional 371,999 shares during the last quarter.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $101.50 on Friday. Mirum Pharmaceuticals has a 12 month low of $43.30 and a 12 month high of $114.99. The stock has a 50 day moving average of $96.89 and a two-hundred day moving average of $89.45. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The firm has a market cap of $6.19 billion, a P/E ratio of -7.46 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The company had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. On average, analysts expect that Mirum Pharmaceuticals will post -2.11 earnings per share for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.